ProteinLogic is developing a novel technology platform (ImmiPrint®) focused on the diagnosis of tuberculosis (TB). Along with HIV/AIDS, TB is the most significant infectious disease worldwide. Early and accurate diagnosis is essential for its control.

The (ImmiPrint®) platform has the potential to deliver an effective blood-based TB diagnostic, and to provide information on disease progression. The test may also be able to predict which individuals are likely to respond to anti-microbial therapy.